Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Trial Timeline
Aug 1, 2011 → Mar 1, 2013
NCT ID
NCT01416948About Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg
Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg is a phase 2 stage product being developed by Brain Biotech for Posttraumatic Stress Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT01416948. Target conditions include Posttraumatic Stress Disorder, Traumatic Brain Injury.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01416948 | Phase 2 | Terminated |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |
| Riluzole | Brain Biotech | Phase 1 | 25 |